Evidence mapPaperPMID 39027470Full record

ArticleFrontiers in endocrinology2024

Rise in fasting and dynamic glucagon levels in children and adolescents with obesity is moderate in subjects with impaired fasting glucose but accentuated in subjects with impaired glucose tolerance or type 2 diabetes.

Thomas Pixner, Tatsiana Chaikouskaya, Wanda Lauth, Georg Zimmermann, Katharina Mörwald, Julia Lischka, Dieter Furthner, Elisabeth Awender, Sabine Geiersberger, Katharina Maruszczak and 5 more

Abstract read
In one paragraph

Article in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Thomas PixnerDepartment of Pediatric and Adolescent Medicine, Salzkammergutklinikum Voecklabruck, Voecklabruck, Austria.
Tatsiana ChaikouskayaInstitut national supérieur des sciences agronomiques de l'alimentation et de l'environnement, Dijon, France.
Wanda LauthBiostatistics and Big Medical Data, Lab for Intelligent Data Analytics (IDA) Salzburg, Paracelsus Medical University, Salzburg, Austria.
Georg ZimmermannBiostatistics and Big Medical Data, Lab for Intelligent Data Analytics (IDA) Salzburg, Paracelsus Medical University, Salzburg, Austria.
Katharina MörwaldObesity Research Unit, Paracelsus Medical University, Salzburg, Austria.
Julia LischkaObesity Research Unit, Paracelsus Medical University, Salzburg, Austria.
Dieter FurthnerDepartment of Pediatric and Adolescent Medicine, Salzkammergutklinikum Voecklabruck, Voecklabruck, Austria.
Elisabeth AwenderObesity Research Unit, Paracelsus Medical University, Salzburg, Austria.
Sabine GeiersbergerObesity Research Unit, Paracelsus Medical University, Salzburg, Austria.
Katharina MaruszczakObesity Research Unit, Paracelsus Medical University, Salzburg, Austria.
Anders ForslundDepartment of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
Christian-Heinz AnderwaldObesity Research Unit, Paracelsus Medical University, Salzburg, Austria.
Janne CadamuroDepartment of Laboratory Medicine, Paracelsus Medical University, Salzburg, Austria.
Daniel WeghuberObesity Research Unit, Paracelsus Medical University, Salzburg, Austria.
Peter BergstenDepartment of Medical Cell Biology, Uppsala University, Uppsala, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Fasting levels of glucagon are known to be elevated in youth and adults with type 2 diabetes mellitus (T2D). Children and adolescents with obesity were previously reported to show increasing fasting and post-glucose-challenge hyperglucagonemia across the spectrum of glucose tolerance, while no data are available in those with impaired fasting glucose (IFG). Materials and methods: Individuals from the Beta-JUDO study population (Uppsala and Salzburg 2010-2016) (n=101, age 13.3 ± 2.8, m/f =50/51) were included (90 with overweight or obesity, 11 with normal weight). Standardized OGTT were performed and plasma glucose, glucagon and insulin concentrations assessed at baseline, 5, 10, 15, 30, 60, 90 and 120 minutes. Patients were grouped according to their glycemic state in six groups with normal glucose metabolism (NGM) and normal weight (NG-NW), NGM with obesity or overweight (NG-O), impaired glucose tolerance (IGT), impaired fasting glucose (IFG), IGT+IFG and T2D, and in two groups with NGM and impaired glucose metabolism (IGM), for statistical analysis. Results and conclusion: Glucagon concentrations were elevated in young normoglycemic individuals with overweight or obesity (NG-O) compared to normoglycemic individuals with normal weight. Glucagon levels, fasting and dynamic, increased with progressing glycemic deterioration, except in IFG, where levels were comparable to those in NG-O. All glycemic groups showed an overall suppression of glucagon during OGTT. An initial increase of glucagon could be observed in T2D. In T2D, glucagon showed a strong direct linear correlation with plasma glucose levels during OGTT. Glucagon in adolescents, as in adults, may play a role in the disease progression of T2D.

Indexed as

Blood GlucoseDiabetes Mellitus, Type 2FastingGlucagonGlucose IntoleranceGlucose Tolerance TestAdolescentChildFemaleHumansInsulinMalePediatric ObesityBlood GlucoseGlucagonInsulindiabetes mellitusglucagoninsulinliver-alpha cell axisobesityOGTTpediatric

Identifiers

PMID39027470
PMCPMC11254805

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.